Aurothioglucose does not improve alveolarization or elicit sustained Nrf2 activation in C57BL/6 models of bronchopulmonary dysplasia

We previously showed that the thioredoxin reductase-1 (TrxR1) inhibitor aurothioglucose (ATG) improves alveolarization in hyperoxia-exposed newborn C3H/HeN mice. Our data supported a mechanism by which the protective effects of ATG are mediated via sustained nuclear factor E2-related factor 2 (Nrf2)...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Am J Physiol Lung Cell Mol Physiol
Päätekijät: Li, Qian, Li, Rui, Wall, Stephanie B., Dunigan, Katelyn, Ren, Changchun, Jilling, Tamas, Rogers, Lynette K., Tipple, Trent E.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Physiological Society 2018
Aiheet:
Rapid Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6008122/
https://ncbi.nlm.nih.gov/pubmed/29368550
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajplung.00539.2017
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia